Vironova Medical's anti-herpes compound

We are developing a topical ointment containing the active ingredient  B-220 for treatment of Herpes labialis – an infection caused by herpes simplex virus-1 (HSV-1).

Herpes - a lifelong disease

Herpes simplex virus 1 (HSV-1) causes a chronic, lifelong infection in >60% of adults and there is currently no cure. The standard treatment Acyclovir can relieve symptoms and marginally shorten outbreaks if taken in time, but not eliminate the virus.

IN THE UNITED STATES, IT IS ESTIMATED THAT APPROXIMATELY 500,000 NEW HSV-1 INFECTIONS OCCUR EVERY YEAR.

Antiviral effect of B-220

Vironova Medical´s compound B-220, first discovered over 4 decades ago, demonstrates a potent broad-spectrum antiviral activity against several viruses from the herpes family i.e. HSV-1, HSV-2, Cytomegalovirus (CMV) and Varicella zoster virus (VZV). It appears to inhibit viral replication at different stages of the virus life cycle, and is more effective compared to Acyclovir. B-220 is approved for topical administration in a US patent.